natgillin/translations-raw huggingface dataset:
No studies in lactating animals have been conducted with the combined active substances of Vipdomet. 
Študije s kombinacijo zdravilnih učinkovin zdravila Vipdomet pri živalih med laktacijo niso bile izvedene.
MARKETING AUTHORISATION NUMBER(S) EU/1/13/843/025 196 (2x98) film-coated tablets (multipack) 
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET EU/1/13/843/025 196 (2x98) filmsko obloženih tablet (večodmerno pakiranje)
MARKETING AUTHORISATION NUMBER(S) EU/1/13/843/025 2x98 film-coated tablets 
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET EU/1/13/843/025 2x98 filmsko obloženih tablet
STATEMENT OF ACTIVE SUBSTANCE(S) Each tablet contains 12.5 mg alogliptin (as benzoate) and 1,000 mg metformin hydrochloride. 
NAVEDBA ENE ALI VEČ UČINKOVIN Ena tableta vsebuje 12,5 mg alogliptina (v obliki benzoata) in 1000 mg metforminijevega klorida.
MARKETING AUTHORISATION NUMBER(S) EU/1/13/843/026 2x98 film-coated tablets 
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET EU/1/13/843/026 2x98 filmsko obloženih tablet
After administration of single oral doses of up to 800 mg in healthy subjects, alogliptin was rapidly absorbed with peak plasma concentrations occurring 1 to 2 hours (median Tmax) after dosing. 
Največje koncentracije v plazmi so bile dosežene 1 do 2 uri (mediana vrednost Tmax) po odmerku.
- Cold symptoms such as sore throat, stuffy or blocked nose, feeling tired, fever, chills, dry cough - Rash - Itchy skin with or without hives - Headache - Indigestion, heartburn - Vomiting and/or diarrhoea - Metallic taste. 
- Prehladu podobni simptomi, kot so boleče žrelo, zamašen nos, občutek utrujenosti, zvišana telesna temperatura, mrzlica, suh kašelj.
Other reactions such as upper respiratory tract infections, nasopharyngitis, headache, gastroenteritis, abdominal pain, diarrhoea, vomiting, gastritis, gastroesophageal reflux disease, pruritus, rash, hypoglycaemia may occur commonly (≥ 1/100 to < 1/10) (see section 4.4) which are attributed to Vipdomet. 
Laktacidoza je resna neželena reakcija, ki se pojavlja zelo redko (<1/10.000) in ki jo je mogoče pripisati vsebnosti metformina v zdravilu Vipdomet (glejte poglavje 4.4).Pogosto (≥1/100 do <1/10) se pojavijo tudi druge reakcije, kot so okužbe zgornjih dihal, nazofaringitis, glavobol, gastroenteritis, bolečina v trebuhu, driska, bruhanje, gastritis, gastroezofagealni refluks, srbenje, izpuščaj, hipoglikemija (glejte poglavje 4.4), ki so posledica uporabe zdravila Vipdomet.
Your blood sugar levels may increase when you stop taking Vipdomet. 
Po prenehanju jemanja zdravila Vipdomet se vrednost krvnega sladkorja lahko zviša.
Vipdomet 12.5 mg/850 mg film-coated tablets 
Vipdomet 12,5 mg/850 mg filmsko obložene tablete alogliptin/metforminijev klorid
Vipdomet 12.5 mg/1,000 mg film-coated tablets 
Vipdomet 12,5 mg/1.000 mg filmsko obložene tablete alogliptin/metforminijev klorid
Vipdomet is not recommended for children and adolescents under 18 years due to the lack of data in these patients. 
Zaradi pomanjkanja podatkov uporaba zdravila Vipdomet pri otrocih in mladostnikih, mlajših od 18 let, ni priporočljiva.
For patients inadequately controlled on dual therapy with a maximal tolerated dose of metformin and pioglitazone, the dose of pioglitazone should be maintained, and Vipdomet administered concomitantly; alogliptin should be dosed at 12.5 mg twice daily (25 mg total daily dose) and metformin hydrochloride at a similar dose (either 850 mg or 1,000 mg twice daily) to that already being taken. 
Odmerek alogliptina mora biti 12,5 mg dvakrat na dan (skupni dnevni odmerek 25 mg), odmerek metforminijevega klorida pa enak tistemu, ki ga bolnik že jemlje (850 mg ali 1.000 mg dvakrat na dan).
Pale yellow, oblong (approximately 22.3 mm long by 10.7 mm wide), biconvex, film-coated tablets with “12.5/1000” debossed on one side and “322M” debossed on the other side. 
Vipdomet 12,5 mg/1000 mg filmsko obložene tablete Bledo rumene, podolgovate (približno 22,3 mm dolge in 10,7 mm široke), bikonveksne, filmsko obložene tablete z vtisnjeno oznako “12.5/1000” na eni in “322M” na drugi strani.
Film-coating 
Bruhanje.
The addition of 25 mg alogliptin once daily to 30 mg pioglitazone in combination with metformin hydrochloride therapy (mean dose = 1,867.9 mg) resulted in improvements from baseline in HbA1c at Week 52 that were both non-inferior and statistically superior to those produced by 45 mg pioglitazone in combination with metformin hydrochloride therapy (mean dose = 1,847.6 mg, Table 3). 
Dodatek alogliptina v odmerku 25 mg enkrat na dan k zdravljenju s 30 mg pioglitazona in z metforminijevim kloridom (povprečni odmerek = 1.867,9 mg) je v 52. tednu povzročil izboljšanja glede na izhodiščne vrednosti HbA1c.
The following section outlines the interactions observed with the individual components of Vipdomet (alogliptin/metformin) as reported in their respective Summary of Product Characteristics. 
(alogliptin/metformin), kot so navedena v njunih povzetkih glavnih značilnosti zdravila.
Light yellow, oblong (approximately 21.0 mm long by 10.1 mm wide), biconvex, film-coated tablets with “12.5/850” debossed on one side and “322M” debossed on the other side. 
Vipdomet 12,5 mg/850 mg filmsko obložene tablete Svetlo rumene, podolgovate (približno 21,0 mm dolge in 10,1 mm široke), bikonveksne, filmsko obložene tablete z vtisnjeno oznako “12.5/850” na eni in “322M” na drugi strani.
This summary was last updated in October 2008. 
Ta povzetek je bil nazadnje posodobljen 10-2008.
In some cases fever may occur for one day, and up to three days in exceptional circumstances. 
V nekaterih primerih se lahko pojavi vročina, ki traja en dan, v izjemnih okoliščinah pa do treh dni.
All studies were performed with Equilis Prequenza Te (comment: double; mentioned in next paragraph). 
Vse študije so izvedli z zdravilom Equilis Prequenza Te (komentar: dvojno; omenjeno v naslednjem odstavku).
Other information about Equilis Te: 
Druge informacije o zdravilu Equilis Te:
The European Commission granted a marketing authorisation valid throughout the European Union, for Equilis Te to Intervet International BV on 8 July 2005. 
Evropska komisija je dovoljenje za promet z zdravilom Equilis Te, veljavno po vsej Evropski uniji, odobrila družbi Intervet International BV dne 8. julija 2005.
Afterwards, a maximum interval of two years is recommended. 
Po tem je najdaljši priporočeni razmik dve leti.
The vaccine also contains an ‘adjuvant' to stimulate a better immune response. 
Cepivo vsebuje tudi „adjuvans“, ki spodbudi boljši imunski odziv.
The Committee recommended that Equilis Te should be given a marketing authorisation. 
Odbor je priporočil, da se za zdravilo Equilis Te odobri dovoljenje za promet.
When the product is given to horses, it helps the animals' immune system to react quicker when the animal is naturally exposed to the Clostridium tetani bacterium. 
Kadar se zdravilo daje konjem, pomaga imunskemu sistemu živali, da reagira hitreje, ko je žival naravno izpostavljena bakteriji Clostridium tetani.
To retain protection against tetanus, horses need to be revaccinated. 
Za ohranitev zaščite proti tetanusu morajo biti konji ponovno cepljeni.
The duration of protection against tetanus was 17 months after primary vaccination and 24 months after the first revaccination. 
Trajanje zaščite proti tetanusu je bilo 17 mesecev po osnovnem cepljenju in 24 mesecev po prvem ponovnem cepljenju.
Horses should receive a primary vaccination, consisting of two injections given four weeks apart. 
Konji potrebujejo osnovno cepljenje, ki vključuje dve injiciranji, ki se izvedeta štiri tedne narazen.
The disease, which usually originates from contaminated wounds, is characterised by overall rigidity (stiffness) and convulsive spasms of the muscles. 
Za bolezen, ki navadno izvira iz okuženih ran, so značilni rigidnost (otrdelost) celotnega telesa in sunkoviti krči mišic.
Horses developed protection two weeks after primary vaccination. 
Konji so razvili zaščito dva tedna po osnovnem cepljenju.
It was concluded that the product is well tolerated by horses of different age. 
Sklenili so, da zdravilo dobro prenašajo konji različnih starosti.
In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the doctor. 
Če pride do nenamernega samoinjiciranja, se takoj posvetujte z zdravnikom in mu pokažite navodilo za uporabo ali nalepko.
What is the risk associated with Equilis Te? 
Kakšna tveganja so povezana z zdravilom Equilis Te?
The toxoid is a toxin processed in order to remove its toxic effect, but retain its antigenic properties. 
Toksoid je toksin, obdelan tako, da odpravi učinek strupa, toda ohrani svoje antigenske lastnosti.
What is the time to allow before the animal can be slaughtered and the meat used for human consumption (withdrawal period)? 
Koliko časa mora preteči, preden se lahko žival zakolje in meso uporabi za prehrano ljudi (obdobje karence)?
The effectiveness of Equilis Te has been studied in several trials under laboratory and field conditions. 
Učinkovitost zdravila Equilis Te so raziskali v več preskušanjih, izvedenih v laboratorijskih in terenskih pogojih.
The safety of Equilis Te was studied in several studies under laboratory and field conditions in a large number of horses, from 2 months of age. 
Varnost zdravila Equilis Te so raziskovali v več študijah, izvedenih v laboratorijskih in terenskih pogojih na številnih konjih, starejših od 2 mesecev.
Equilis Te is a vaccine for use in horses. 
Zdravilo Equilis Te je cepivo, ki se uporablja za konje.
The first revaccination should be no later than 17 months after primary vaccination. 
Prvo ponovno cepljenje se mora izvesti najpozneje v 17 mesecih po osnovnem cepljenju.
Horses belong to the most susceptible species to tetanus. 
Konji so med živalskimi vrstami najbolj občutljivi na tetanus.
What benefit has Equilis Te shown during the studies? 
Kakšne koristi je zdravilo Equilis Te izkazalo med študijami?
Studies in pregnant mares were also performed. 
Študije so izvedli tudi na brejih kobilah.
The main measure of effectiveness was the production of protective levels of antibodies against tetanus toxoid after vaccination. 
Glavno merilo učinkovitosti je bilo tvorjenje zaščitnih ravni protiteles proti toksoidu tetanusa po cepljenju.
Pain at the injection site can occur occasionally. 
Občasno je možna bolečina na mestu dajanja.
Tetanus is an acute, often fatal disease caused by a neurotoxin produced by the bacterium Clostridium tetani. 
Tetanus je akutna bolezen, ki ima pogosto smrten izid, povzroča pa jo nevrotoksin, ki ga proizvaja bakterija Clostridium tetani.
This helps to protect against tetanus. 
S tem pomagamo zaščititi žival proti tetanusu.
Equilis Te is a vaccine containing purified tetanus toxoid. 
Zdravilo Equilis Te je cepivo, ki vsebuje prečiščen toksoid tetanusa.
Why has Equilis Te been approved? 
Zakaj je bilo zdravilo Equilis Te odobreno?
It contains the toxoid (chemically inactivated toxin) from the tetanus bacterium. 
Vsebuje toksoid (kemično oslabljen toksin) iz bakterije tetanusa.
Most of the studies were performed with Equilis Prequenza Te, a vaccine that protects against equine influenza as well as against tetanus. 
Večino študij so izvedli z zdravilom Equilis Prequenza Te, cepivom, ki ščiti tako proti influenci konj kot tudi proti tetanusu.
The studies showed that Equilis Te is an effective vaccine against tetanus to prevent mortality in horses from 6 months of age. 
Študije so pokazale, da je zdravilo Equilis Te učinkovito cepivo proti tetanusu za preprečevanje umrljivosti pri konjih, ki so starejši od 6 mesecev.
The Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of Equilis Te exceeded the risks for the immunisation of horses from six months of age against tetanus to prevent mortality. 
Odbor za zdravila za uporabo v veterinarski medicini (CVMP) je zaključil, da so koristi zdravila Equilis Te pri imunizaciji konj, ki so starejši od šest mesecev, proti tetanusu za preprečevanje umrljivosti večje od z njim povezanih tveganj.
Swelling (max. diameter 5 cm) may occur at the injection site, either as diffuse hard or soft swelling. 
Lahko se pojavi neostro omejena trda ali mehka oteklina (premera največ 5 cm) na mestu dajanja.
Equilis Te is used to vaccinate horses from six months of age against tetanus to prevent mortality. 
Zdravilo Equilis Te se uporablja za cepljenje konj, ki so starejši od šestih mesecev, proti tetanusu za preprečevanje umrljivosti.
No negative influence on gestation, foaling and offspring of mares was observed after vaccination at different times during pregnancy. 
Po cepljenju v različnih obdobjih brejosti niso opazili nobenih negativnih učinkov na brejost, žrebitev in mladiče.
How has Equilis Te been studied? 
Kako je bilo zdravilo Equilis Te raziskano?
How does Equilis Te work? 
Kako zdravilo Equilis Te deluje?
What is Equilis Te used for? 
Za kaj se zdravilo Equilis Te uporablja?
What is Equilis Te? 
Kaj je zdravilo Equilis Te?
The withdrawal period of the product is zero days. 
Obdobje karence zdravila je nič dni.
If the symptoms persist for more than 2 weeks, a doctor or a qualified health care practitioner should be consulted. 
Če simptomi trajajo dlje kot 2 tedna, se je treba posvetovati z zdravnikom ali usposobljenim zdravstvenim delavcem.
Fresh bilberry fruit EMA/680058/2015 
Svež plod borovnice EMA/680058/2015
In its assessment, the HMPC also considered clinical studies on disorders of the circulatory system which were performed 30 - 40 years ago. 
V svoji oceni je odbor HMPC prav tako upošteval klinične študije o motnjah obtočil, ki so bile izvedene pred 30-40 leti.
Fresh bilberry fruit medicines should only be used in adults and should not be taken for longer than 4 weeks. 
Zdravila, ki vsebujejo svež plod borovnice, se smejo uporabljati samo pri odraslih in se ne smejo uporabljati več kot 4 tedne.
This summary is not intended to provide practical advice on how to use medicines containing fresh bilberry fruit. 
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o uporabi zdravil, ki vsebujejo svež plod borovnice.
This is a summary of the scientific conclusions reached by the Committee on Herbal Medicinal Products (HMPC) on the medicinal uses of fresh bilberry fruit. 
To je povzetek znanstvenih zaključkov Odbora za zdravila rastlinskega izvora (HMPC) v zvezi z medicinsko uporabo svežega plodu borovnice.
Although possible beneficial effects were observed, there were limitations in the way the studies were conducted and, therefore, the HMPC conclusions on the use of fresh bilberry fruit medicines are based on their long-standing use. 
Čeprav so bili ugotovljeni možni koristni učinki, so bile pri izvedbi študij pomanjkljivosti in zato zaključki odbora HMPC v zvezi z uporabo zdravil, ki vsebujejo svež plod borovnice, temeljijo na njihovi dolgotrajni uporabi.
Further information on the risks associated with fresh bilberry fruit medicines, including the appropriate precautions for their safe use, can be found in the monograph under the tab ‘All documents' on the Agency's website: ema.europa.eu/Find medicine/Herbal medicines for human use. 
Dodatne informacije o tveganjih, povezanih z zdravili, ki vsebujejo svež plod borovnice, vključno z ustreznimi previdnostnimi ukrepi za njihovo varno uporabo, so na voljo v monografiji na spletni strani agencije pod zavihkom „Vsi dokumenti“: ema.europa.eu/Find medicine/Herbal medicines for human use.
Fresh bilberry fruit 
Svež plod borovnice
Herbal medicines containing fresh bilberry fruit preparations are usually available in solid forms to be taken by mouth. 
Zdravila rastlinskega izvora, ki vsebujejo pripravke s svežim plodom borovnice, so navadno na voljo v trdni obliki za jemanje skozi usta.
Fresh bilberry fruit is the common name for the fresh fruit of the plant Vaccinium myrtillus L. Fresh bilberry fruit preparations are obtained using a technique to extract compounds from fresh plant material by dissolving them in a solvent (such as methanol), which is then evaporated to obtain a dry extract. 
Svež plod borovnice je splošno ime za svež plod rastline Vaccinium myrtillus L. Pripravki s svežim plodom borovnice se pridobivajo z uporabo tehnike, s katero se spojine ekstrahirajo tako, da se svež rastlinski material najprej namoči v topilo (npr. metanol), v katerem se raztopijo spojine.
The anthocyanins are also thought to repair tiny blood vessels after damage to the local circulation. 
Antocianini naj bi prav tako popravljali kapilare po poškodbi lokalnega obtoka.
The HMPC conclusions are taken into account by EU Member States when evaluating applications for the licensing of herbal medicines containing fresh bilberry fruit. 
Ugotovitve odbora HMPC države članice EU upoštevajo pri ocenjevanju vlog za izdajo dovoljenja za promet z zdravili rastlinskega izvora, ki vsebujejo svež plod borovnice.
What is fresh bilberry fruit? 
Kaj je svež plod borovnice?
Further information on the HMPC assessment of fresh bilberry fruit medicines, including details of the Committee's conclusions, can be found under the tab ‘All documents' on the Agency's website: ema.europa.eu/Find medicine/Herbal medicines for human use. 
Dodatne informacije o oceni zdravil, ki vsebujejo svež plod borovnice, ki jo je opravil odbor HMPC, vključno z njegovimi znanstvenimi zaključki, so na voljo na spletni strani agencije pod zavihkom „Vsi dokumenti“: ema.europa.eu/Find medicine/Herbal medicines for human use.
Any applications for the licensing of medicines containing fresh bilberry fruit have to be submitted to the national authorities responsible for medicinal products, which will assess the application for the herbal medicine and take into account the scientific conclusions of the HMPC. 
Vlogo za izdajo dovoljenja za promet z zdravili, ki vsebujejo svež plod borovnice, je treba predložiti pristojnemu nacionalnemu organu za zdravila, ki bo to vlogo za izdajo dovoljenja za promet z zdravilom rastlinskega izvora ocenil in upošteval znanstvene zaključke odbora HMPC.
Information on the use and licensing of fresh bilberry fruit medicines in EU Member States should be obtained from the relevant national authorities. 
Za informacije o uporabi in registraciji zdravil, ki vsebujejo svež plod borovnice, v državah članicah EU se obrnite na pristojni nacionalni organ.
The HMPC conclusions on the use of fresh bilberry fruit medicines for relief of discomfort and heaviness of legs related to minor blood circulatory problems and for relief of symptoms of bleeding into the skin from tiny blood vessels are based on their ‘traditional use'. 
Zaključki odbora HMPC o uporabi zdravil, ki vsebujejo svež plod borovnice, za lajšanje neugodja in težkih nog, povezanih z manjšimi težavami z obtočili, in za lajšanje simptomov krvavitve v kožo iz kapilar, temeljijo na njihovi „tradicionalni uporabi“.
Results from laboratory studies indicate that bilberries are rich in anthocyanins, which are thought to improve blood circulation by relaxing and dilating (widening) blood vessels and protecting blood vessels from damage. 
Rezultati laboratorijskih študij kažejo, da so borovnice bogate z antocianini, ki naj bi s sproščanjem in dilatacijo (širjenjem) žil in zaščito žil pred poškodbami izboljševali krvni obtok.
How are fresh bilberry fruit medicines approved in the EU? 
Kako so zdravila, ki vsebujejo svež plod borovnice, odobrena v EU?
The HMPC concluded that, on the basis of its long-standing use, fresh bilberry fruit medicines can be used to relieve discomfort and heaviness of legs related to minor blood circulatory problems and to relieve symptoms of bleeding into the skin from tiny blood vessels. 
Odbor HMPC je na podlagi dolgotrajne uporabe zaključil, da se lahko zdravila, ki vsebujejo svež plod borovnice, uporabljajo za lajšanje neugodja in težkih nog, povezanih z manjšimi težavami z obtočili, in za lajšanje simptomov krvavitve v kožo iz kapilar.
Other information about fresh bilberry fruit medicines 
Druge informacije o zdravilih, ki vsebujejo svež plod borovnice
Detailed instructions on how to take fresh bilberry fruit medicines and who can use them can be found in the package leaflet that comes with the medicine. 
Podrobna navodila o jemanju zdravil, ki vsebujejo svež plod borovnice, in o tem, kdo sme ta zdravila jemati, so na voljo v navodilu za uporabo, ki je priloženo posameznemu zdravilu.
What evidence supports the use of fresh bilberry fruit medicines? 
Kateri dokazi podpirajo uporabo zdravil, ki vsebujejo svež plod borovnice?
What are the risks associated with fresh bilberry fruit medicines? 
Kakšna tveganja so povezana z zdravili, ki vsebujejo svež plod borovnice?
For more information about treatment with fresh bilberry fruit medicines, read the package leaflet that comes with the medicine or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravili, ki vsebujejo svež plod borovnice, preberite navodilo za uporabo, ki je priloženo posameznemu zdravilu, ali se posvetujte z zdravnikom ali farmacevtom.
For practical information about using fresh bilberry fruit medicines, patients should read the package leaflet that comes with the medicine or contact their doctor or pharmacist. 
Za praktične informacije o njihovi uporabi naj bolniki preberejo navodilo za uporabo, ki je priloženo posameznemu zdravilu, ali se posvetujejo z zdravnikom ali farmacevtom.
This summary was last updated in 05-2016 
Povzetek je bil nazadnje posodobljen 05-2016.
Jentadueto must not be used in patients with: 
Zdravila Jentadueto ne smejo uporabljati bolniki z:
The European Commission granted a marketing authorisation valid throughout the European Union for Jentadueto on 20 July 2012. 
Evropska komisija je dovoljenje za promet z zdravilom Jentadueto, veljavno po vsej Evropski uniji, izdala 20. julija 2012.
Jentadueto is taken twice a day. 
Zdravilo Jentadueto se jemlje dvakrat na dan.
The full EPAR for Jentadueto can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Jentadueto je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
This is a summary of the European public assessment report (EPAR) for Jentadueto. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Jentadueto.
Other information about Jentadueto 
Druge informacije o zdravilu Jentadueto
What extra measures are being taken to ensure the safe and effective use of Jentadueto? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Jentadueto?
Linagliptin is a dipeptidyl-peptidase-4 (DPP 4) inhibitor. 
Linagliptin je zaviralec dipeptidil-peptidaze-4 (DPP 4).
Linagliptin has been authorised in the European Union (EU) as Trajenta since 2011. 
Linagliptin je v Evropski uniji (EU) odobren od leta 2011 kot zdravilo Trajenta.
For more information about treatment with Jentadueto, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Jentadueto preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
With regard to side effects, the Committee considered that in general the risks seen were only slightly greater than those seen with placebo. 
Glede neželenih učinkov je menil, da so bila opažena tveganja na splošno samo rahlo večja od tistih pri uporabi placeba.
The CHMP noted that fixed dose combinations may increase the likelihood of patients taking their medicine correctly. 
Ugotovil je, da lahko fiksne kombinacije odmerkov povečajo verjetnost, da bodo bolniki zdravilo pravilno jemali.
• diabetic ketoacidosis or diabetic pre-coma (dangerous complications of diabetes); 
• diabetično ketoacidozo ali predkomo (nevarnima zapletoma sladkorne bolezni);
• a condition that could lead to reduced supply of oxygen to body tissues (such as in patients who are being treated for worsening heart failure, have recently had a heart attack, have difficulty breathing or a steep fall in blood pressure); 
• obolenjem, ki lahko povzroči zmanjšano dovajanje kisika v tkiva (npr. pri bolnikih, ki se zdravijo zaradi srčnega popuščanja, so pred kratkim doživeli srčni napad, imajo oteženo dihanje ali nenaden padec krvnega tlaka);